Hypertrophic cardiomyopathy medical therapy: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
{{Hypertrophic cardiomyopathy}} | {{Hypertrophic cardiomyopathy}} | ||
'''Editors-In-Chief:''' [[C. Michael Gibson, M.S., M.D.]] [mailto:mgibson@perfuse.org] | '''Editors-In-Chief:''' [[C. Michael Gibson, M.S., M.D.]] [mailto:mgibson@perfuse.org] | ||
==Overview== | ==Overview== | ||
The medical management of the patient with hypertrophic cardiomyopathy involves minimizing diastolic dysfunction, reducing left ventricular outflow tract obstruction, optimizing [[heart failure]] management, maintaining [[normal sinus rhythm]], rate control and anticoagulation in the presence of [[atrial fibrillation]]), and implantation of an [[automatic implantable cardiac defibrillator]] in those patients who survive [[sudden cardiac death]]. | |||
==References== | ==References== | ||
Revision as of 23:27, 7 August 2011
|
Hypertrophic Cardiomyopathy Microchapters |
|
Differentiating Hypertrophic Cardiomyopathy from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hypertrophic cardiomyopathy medical therapy On the Web |
|
Directions to Hospitals Treating Hypertrophic cardiomyopathy |
|
Risk calculators and risk factors for Hypertrophic cardiomyopathy medical therapy |
Editors-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
The medical management of the patient with hypertrophic cardiomyopathy involves minimizing diastolic dysfunction, reducing left ventricular outflow tract obstruction, optimizing heart failure management, maintaining normal sinus rhythm, rate control and anticoagulation in the presence of atrial fibrillation), and implantation of an automatic implantable cardiac defibrillator in those patients who survive sudden cardiac death.